Transplant
From the Journals
Several factors may drive recent improvements in allo-HCT outcomes
Patients transplanted in recent years were older and sicker at baseline but had better outcomes than did patients transplanted in the mid-2000s....
Conference Coverage
Myeloma patients over age 70 can benefit from auto-HC transplant
ORLANDO – Researchers said all myeloma patients should be referred a transplant center, regardless of age.
Feature
First NCCN guideline on hematopoietic cell transplantation focuses on GVHD
Diagnosis and management of both acute and chronic graft-versus-host disease is at the core of the recommendations.
From the Journals
Hematopoietic cell transplant offers realistic cure in secondary AML
The observational trial showed that survival was significantly higher with transplant than with chemotherapy consolidation therapy in patients...
News
Daratumumab approved in combo with VTd for transplant-eligible multiple myeloma
This marks the drug’s second approved indication this year and its seventh overall.
Feature
Ongoing research aims to improve transplant outcomes in sickle cell
Over the past 2 years, the majority of novel transplant techniques have been primarily aimed at improving conditioning regimens and lowering rates...
From the Journals
Several factors may affect immune suppression discontinuation after HCT
Older age, advanced stage disease, having a mismatched unrelated donor, and receiving peripheral blood stem cells from an unrelated donor were...
From the Journals
ASCT may cure follicular lymphoma for some rituximab-naive patients
A retrospective cohort study suggests that ASCT, if performed promptly, can be curative in patients who have had an early failure of first-line...
Feature
Could home care replace inpatient HSCT?
Researchers are conducting phase 2 trials comparing patients who receive all posttransplant care at home with patients treated in the hospital or...
From the Journals
VRD pretransplant induction deepens responses in myeloma
The researchers wrote that the unique dosing of the three-drug induction regimen may be considered a new standard of care.
From the Journals
Stem cells gene edited to be HIV resistant treat ALL, but not HIV